Cellectis SA (CLLS) Receives a Buy from Oppenheimer

By Ryan Adsit

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Cellectis SA (CLLSResearch Report) today and set a price target of $44. The company’s shares opened today at $19.58.

Singh said:

“Cellectis (CLLS) announced on 4/2 that its allogeneic program targeting CS1 (SLAMF7) for multiple myeloma (MM) had entered the clinic. This continues CLLS’s accelerating pace of clinical development with UCART123 entering the clinic in 3Q17 and UCART22 in 2Q18. We believe that such momentum of preclinical projects moving into the clinic validates CLLS’s learnings on its gene editing and manufacturing platform, with CLLS also recently committing to scaling its clinical/ commercial manufacturing footprint. We also like the CS1 target in MM, since this target has been validated with the approval of antibody elotuzumab for multiple myeloma, while the BCMA approach for MM is cluttered with some notable early- study terminations. We stay bullish on the name.”

According to TipRanks.com, Singh is a 4-star analyst with an average return of 3.8% and a 47.3% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Catabasis Pharmaceuticals.

Cellectis SA has an analyst consensus of Strong Buy, with a price target consensus of $38.67, representing a 97.5% upside. In a report released today, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.09 and a one-year low of $15.34. Currently, Cellectis SA has an average volume of 139.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.